Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Solid Tumors 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × amivantamab × Thoracic × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡